These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 28411254)

  • 1. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.
    Cines DB; Wasser J; Rodeghiero F; Chong BH; Steurer M; Provan D; Lyons R; Garcia-Chavez J; Carpenter N; Wang X; Eisen M
    Haematologica; 2017 Aug; 102(8):1342-1351. PubMed ID: 28411254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romiplostim or standard of care in patients with immune thrombocytopenia.
    Kuter DJ; Rummel M; Boccia R; Macik BG; Pabinger I; Selleslag D; Rodeghiero F; Chong BH; Wang X; Berger DP
    N Engl J Med; 2010 Nov; 363(20):1889-99. PubMed ID: 21067381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
    Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.
    Kuter DJ; Bussel JB; Newland A; Baker RI; Lyons RM; Wasser J; Viallard JF; Macik G; Rummel M; Nie K; Jun S
    Br J Haematol; 2013 May; 161(3):411-23. PubMed ID: 23432528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
    Steurer M; Quittet P; Papadaki HA; Selleslag D; Viallard JF; Kaiafa G; Janssens A; Kozak T; Wadenvik H; Schoonen M; Belton L; Kreuzbauer G
    Eur J Haematol; 2017 Feb; 98(2):112-120. PubMed ID: 27557853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
    Jamali F; Lemery S; Ayalew K; Robottom S; Robie-Suh K; Rieves D; Pazdur R
    Oncology (Williston Park); 2009 Jul; 23(8):704-9. PubMed ID: 19711585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM
    Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.
    Kuter DJ; Mathias SD; Rummel M; Mandanas R; Giagounidis AA; Wang X; Deuson RR
    Am J Hematol; 2012 May; 87(5):558-61. PubMed ID: 22460421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
    Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
    Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G
    Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
    Janssens A; Rodeghiero F; Anderson D; Chong BH; Boda Z; Pabinger I; Červinek L; Terrell DR; Wang X; Franklin J
    Ann Hematol; 2016 Jun; 95(7):1077-87. PubMed ID: 27130310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
    Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
    Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia.
    Weitz I; Sanz MA; Henry D; Schipperus M; Godeau B; Northridge K; Gleeson M; Danese M; Deuson R
    Curr Med Res Opin; 2012 May; 28(5):789-96. PubMed ID: 22494019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.